VACCINE USAGE: HAVRIX is a vaccine indicated for active immunization against disease caused by hepatitis A virus (HAV). HAVRIX is approved for use in persons 12 months of age and older. Primary immunization should be administered at least 2 weeks prior to expected exposure to HAV.

VACCINE DOSAGE: HAVRIX is administered by intramuscular injection.

  • Children and adolescents: A single 0.5-mL dose and a 0.5-mL booster dose administered between 6 to 12 months later.
  • Adults: A single 1-mL dose and a 1-mL booster dose administered between 6 to 12 months later.

VACCINE INGEDIENTS: aluminum hydroxide, amino acid supplement, polysorbate 80, formalin, neomycin sulfate, MRC-5 cellular proteins.

ADVERSE VACCINE REACTIONS: anorexia, nausea, fatigue, fever, pharyngitis, upper respiratory tract infection, lymphadenopathy, insomnia, dysgeusia, hypertonia, photophobia, vertigo, abdominal pain, diarrhea, vomiting, pruritus, rash, urticaria, arthralgia, myalgia, injection site hematoma, creatine phosphokinase increased, rhinitis, hepatitis, jaundice, angioedema, erythema, multiforme, congenital anomaly, musculoskeletal stiffness.